PTPI
Petros Pharmaceuticals, Inc.NASDAQHealthcare$0.01+0.00%ClosedMarket Cap: $155,801
As of 2026-04-07
Valuation
P/E (TTM)
—
PEG
—
P/B
0.07
P/S
0.23
EV/EBITDA
0.50
DCF Value
$-2.87
FCF Yield
-2931.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
63.5%
Operating Margin
-1844.6%
Net Margin
-968.2%
ROE
304.1%
ROA
-114.5%
ROIC
-397.3%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q3 2025 | $0.00 | NaN% | $-990.7K | $-922.7K | $-0.03 | — |
| Q2 2025 | $0.00 | NaN% | $-1.8M | $5.4M | $-1.29 | — |
| Q1 2025 | $0.00 | NaN% | $-1.5M | $-2.3M | $-9.37 | — |
| Q4 2024 | $725.4K | 63.5% | $-9.1M | $-9.3M | $-0.13 | — |
| FY 2024 | $5.1M | 76.3% | $-17.7M | $-14.3M | $-3.34 | — |
| Q3 2024 | $1.6M | 81.8% | $-2.3M | $-2.2M | $-0.53 | — |
| Q2 2024 | $1.4M | 76.8% | $-2.3M | $-662.0K | $-0.37 | — |
| Q1 2024 | $1.4M | 24.4% | $-3.9M | $-2.2M | $-1.69 | — |
| Q4 2023 | $-364.3K | 143.4% | $-5.0M | $318.1K | $-2.10 | — |
| FY 2023 | $5.8M | 72.0% | $-13.6M | $-8.2M | $-6.35 | — |
| Q3 2023 | $1.7M | 75.6% | $-4.8M | $-4.5M | $-2.85 | — |
| Q2 2023 | $2.0M | 74.2% | $-2.5M | $-2.5M | $-1.20 | — |